AbbVie Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Q1 Earnings Showdown: ABBV vs. Therapeutics Stocks!

📉 Q1 2023 revenue fell ~10% YoY to $12.23 billion and adjusted EPS dropped 22% to $2.46 due to Humira's patent expiration.

💰 AbbVie raised its quarterly dividend by 4.7% to $1.55, bringing the total annualized yield to approximately 3%–3.5%, above the industry median.

🏦 Total debt stands at $59.4 billion as of year-end 2023, with significant maturities of ~$7.2 billion due in 2024 and ~$8.8 billion in 2025.

💵 Operating cash flow reached $22.8 billion in 2023, providing roughly 2.2x coverage for the $10.5 billion in dividends paid.

📈 New immunology drugs Skyrizi and Rinvoq grew rapidly in 2023 with sales of $7.8 billion and $4.0 billion respectively, offsetting Humira's decline.

⚠️ Global Humira revenue dropped 32% in 2023, creating a major near-term earnings headwind as the company transitions its portfolio.

📉 Oncology drug Imbruvica revenues fell 21% in 2023 due to competition, resulting in a $3.6 billion impairment charge.

⚖️ Credit rating agencies upgraded AbbVie to A- (S&P) and A3 (Moody's), reflecting confidence in its deleveraging progress.

📉 Forward P/E ratio is estimated at 15–17x, which is reasonable for a large pharma peer despite elevated trailing multiples.

🏛️ U.S. Medicare price negotiations will target Imbruvica by 2026, potentially eroding revenue from this key franchise.

💸 AbbVie holds $12.8 billion in cash and has been actively reducing debt, paying down over $4 billion net in 2023.

📉 Contingent payment liabilities related to acquisitions increased by $5.1 billion in 2023 due to higher Skyrizi sales.

Bullish Signals
  • AbbVie raised its quarterly dividend by 4.7% to $1.55, resulting in a total annualized yield of approximately 3%–3.5%, which exceeds the pharmaceutical industry median.
  • The company generated $22.8 billion in operating cash flow in 2023, comfortably covering its $10.5 billion dividend payments and capital expenditures with free cash flow coverage of roughly 2.2x.
  • New immunology products Skyrizi and Rinvoq demonstrated strong growth in 2023 with sales increases of 51% and 58% respectively, reaching combined sales of nearly $12 billion.
  • Credit rating agencies upgraded AbbVie to A- (S&P) and A3 (Moody's), signaling confidence in the company's ability to manage its debt load and cash flow outlook.
  • AbbVie has successfully deleveraged its balance sheet, reducing total debt by over $4 billion net in 2023 while maintaining a robust cash balance of $12.8 billion.
Risk Factors
  • Q1 2023 revenue declined ~10% year-over-year to $12.23 billion, and adjusted EPS fell 22% to $2.46, driven by the loss of exclusivity on Humira.
  • Global Humira revenue dropped 32% in 2023, with U.S. sales falling 35%, creating a significant near-term earnings headwind as the company transitions its portfolio.
  • Oncology franchise Imbruvica saw revenues fall 21% in 2023 due to competition, leading to a $3.6 billion impairment charge related to underperforming assets.
  • AbbVie faces large contingent payment liabilities of nearly $20 billion at fair value, which increased by $5.1 billion in 2023 due to higher Skyrizi sales.
Full Analysis
AbbVie Inc. (NYSE: ABBV) reported Q1 2023 revenue of $12.23 billion, a ~10% year-over-year decline, and adjusted EPS of $2.46, down 22%, primarily due to the anticipated impact of Humira's patent expiration. Despite this earnings contraction, the company maintained resilient performance with strong cash generation, paying $10.5 billion in dividends during 2023 and raising its quarterly dividend by 4.7% to $1.55 per share effective February 2024. The article details AbbVie's substantial debt load of $59.4 billion as of year-end 2023, largely stemming from the 2020 Allergan acquisition, though the company has proactively deleveraged by repaying over $4 billion in net debt in 2023. With a cash balance of $12.8 billion and operating cash flow of $22.8 billion in 2023, AbbVie comfortably covers its capital expenditures and dividend obligations, supported by credit upgrades to A- (S&P) and A3 (Moody's). Key risks include the significant decline in Humira sales, which dropped 32% globally in 2023, and the challenge of replacing its ~$20 billion annual revenue peak with newer immunology drugs like Skyrizi ($7.8 billion) and Rinvoq ($4.0 billion). The company also faces regulatory headwinds such as Medicare price negotiations for Imbruvica starting in 2026, potential safety warnings for JAK inhibitors, and large contingent payment liabilities related to past acquisitions.